skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: I have a small (1%) position in Solium and am up modestly. I was pleasantly surprised at the modest share price bump after the poor Q2/1H earnings. Perhaps the market is looking at the improved topline and giving the company time to convert that to a better bottom line. However, I'm thinking of selling SUM and buying more GUD, which is also a small position. I could also keep SUM and just add to GUD. Could you provide an outlook on SUM for the next 2-3 years and the relative merits of these two? Thank-you.
Read Answer Asked by David on August 19, 2016
Q: A year ago, Knight signed a deal to distribute 3 of Advaxis's products in Canada and bought about 400,000 shares at $13.91, a premium at the time from the Advaxis treasury. The shares tanked to $5, recovered to $8 and have jumped %6 to $14 in the past 3 days on the announcement that Amgen bought worldwide rights to another Advaxis drug and gave them $40 Million. This will help Knight as the shares appreciate but will it hurt their deal on the other 3 drugs they represent as Advaxis may concentrate on the behemoth deal with a super-large pharma co. and neglect their other products.
Knight's share price has help up well during the healthcare decline. Do you think they will one day do a big deal or continue to drip out their $600M in miniscule does? I am sure this company will be a blockbuster some day, but I may not live long enough to see it!
Thanks.
Read Answer Asked by Steven on August 05, 2016
Q: I would like to increase my investment in the Canadian health care sector. I am looking for yield. What are your top recommendations? I already have enough Sienna (SIA) and Chartwell (CSH.UN). Pharmaceuticals and laboratories interest me.
Read Answer Asked by Carl on August 04, 2016
Q: Hello Peter,
I was expecting Fairfax, CRH medical, and Constellation to go up significantly after the earnings announcement. Fairfax dipped, CRH and CSU went up slightl. Any comments please? Do you think it is too late to enter Electrovaya at 3.40 or above? Also, do you think Knight (gud) is a type of stock you can buy and hold it for years given the credibility of the management team? Thanks very much.
Read Answer Asked by umedali on August 02, 2016
Q: i read every question and answer everyday and 3 of your favorite companies and 3 companies you continually recommend are shopify, knight and kinaxis.i am overweight all 3. and all 3 are in your model portfolios.
we know knight is protected by its huge cash balance and once it is gone the parameters would change hopefully for the better depending how goodman spends it.
you keep making reference to shopify and kinaxis being expensive, earnings for both aug.3 and aug 4. my question is anything that i should be aware of before earnings. dave
Read Answer Asked by david on July 15, 2016
Q: I own these 4 stocks in my TFSA account in which SIS is 2% holding overall all accounts and the other 3 are 1% overall. From reading the questions that have been asked on theses 4 stocks , you feel that DRT is a hold as well as GUD? I would like to increase my holdings so do think that it would be best to add to PLI and SIS at this time and not GUD or DRT?

Thanks
Dolores
Read Answer Asked on July 06, 2016
Q: Is the etf VE okay in my cash savings (taxable) account? There is no more room in my TFSA.
Based on my research, the inception date for FEZ is Oct 15, 2002. The inception date for VE is June 30, 2014. Loblaws became buyable on the stock market January 18, 1956. What is the similar date for GUD? From, Patti.
Read Answer Asked by Patti on June 16, 2016
Q: I hold these 3 plus XLV in the health care portion of my portfolio. Not adverse to risk but I am wondering whether CXR is worth the grief. Is there a case for focussing on the others, or does the risk/reward of CXR make it worthwhile holding?
Read Answer Asked by Alan on June 08, 2016
Q: If you could please comment on this U.S. company IMS Healthcare. I would greatly appreciate it. Can you classify it as tech or healthcare and how it compares to its historical data PE/PCF/PB and any other fundamental that is important to you. Would you still prefer GUD over this stock? My worry with GUD is that they do not use their cash and investors become irritated and fickle. I can benefit from IMS as it diversifies my portfolio a little more to the US.I am thinking of a 1 to 3 year hold minimum. Thank You
Read Answer Asked by Jeremy on May 30, 2016
Q: Good Afternoon,
I see that you recently answered a question on the $200MM bought deal today, I would just like to expand on this a bit please. I recall when Avigilon did this a few years ago, they already had ample cash on the balance sheet with no debt but took advantage of their high share price to issue shares and raise capital. You had mentioned at the time that they likely had a large acquisition in mind but they never really did deploy that excess cash with one single large takeover that I recall. Of course AVO has unperformed and acting poorly ever since. Any read through on GUD? They now have approximately 75% of their market cap as cash, seems awfully high with now 25% more shares outstanding. Doesn't seem to make much sense? Any further thoughts? Thank-you.
Read Answer Asked by Chris on May 11, 2016
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!